Comparison of clinical and endoscopic efficacy between vedolizumab and infliximab in bio-naive patients with ulcerative colitis: a multicenter, real-world study.

ABSTRACT:

Background

No head-to-head trial directly compares the effectiveness of vedolizumab (VDZ) and infliximab (IFX) in patients with ulcerative colitis (UC) who were naïve to biologic therapy.

Objectives

We aimed to compare the clinical and endoscopic effectiveness of VDZ and IFX in biologic-naïve patients with UC in real-world settings.

Design

It was a multicenter, observational, real-world cohort study conducted at five centers.

Methods

Patients diagnosed with UC and treated with either IFX or VDZ as their first-line biologic therapy were retrospectively enrolled. Steroid-free remission, clinical response, clinical remission, and endoscopic healing at week 14 and week 52 were compared between the two groups after propensity score weighting.

Results

A total

SUBMITTER: Huang Z 

PROVIDER: S-EPMC11483708 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature